Confronto
Ganirelix vs. Goserelin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
123246-29-7
65807-02-5
Peso molecolare
1570.3 g/mol
1269.43 g/mol
Emivita
nessun dato
4.2 h
Sequenza
nessun dato
pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2Meccanismo d'azione
Ganirelix
Ganirelix competitively and reversibly binds the pituitary GnRH receptor, rapidly suppressing LH (and, less so, FSH) release — without the initial hormone 'flare' of GnRH agonists.
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
1
4
di cui sull'uomo
1
4
Effetti registrati
2
3
Contraddizioni aperte
0
1
Eventi avversi documentati
1
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Ganirelix and Goserelin?
- Ganirelix is classified as "Ricerca (altro)", while Goserelin is classified as "Ricerca (altro)". Ganirelix: Ganirelix is a synthetic decapeptide and GnRH antagonist. In assisted reproduction (IVF) it prevents the premature LH surge during controlled ovarian stimulation. Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Ganirelix or Goserelin?
- The highest available evidence level is "RCT sull'uomo" for Ganirelix and "RCT sull'uomo" for Goserelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Ganirelix and Goserelin in Germany and the United States?
- Germania: Ganirelix — Su prescrizione, Goserelin — Su prescrizione. Stati Uniti: Ganirelix — Su prescrizione, Goserelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.